A Randomized, Double-Blind, Parallel-Group, Dose-Response Study of Micafungin Compared with Fluconazole for the Treatment of Esophageal Candidiasis in HIV-Positive Patients
Open Access
- 15 September 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (6), 842-849
- https://doi.org/10.1086/423377
Abstract
Background. Severely immunocompromised individuals are highly susceptible to Candida infection of the esophagus. This randomized, double-blind study assessed the dose-response relationship of the new echinocandin antifungal, micafungin, compared with that of standard fluconazole treatment.Keywords
This publication has 20 references indexed in Scilit:
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- Invasive Oesophageal CandidiasisDrugs, 2003
- Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with CaspofunginAIDS Research and Human Retroviruses, 2002
- Antifungal use in HIV infectionExpert Opinion on Pharmacotherapy, 2002
- Refractory Mucosal Candidiasis in Advanced Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2000
- Fluconazole vs. Flucytosine in the Treatment of Esophageal Candidiasis in AIDS Patients: A Double-Blind, Placebo-Controlled StudyEndoscopy, 1995
- Fluconazole Compared with Itraconazole in the Treatment of Esophageal Candidiasis in AIDS Patients: A Double-blind, Randomized, Controlled Clinical StudyScandinavian Journal of Infectious Diseases, 1995
- Some Methods for Strengthening the Common χ 2 TestsBiometrics, 1954
- A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVESBiometrika, 1954